A Universal Framework for the Benefit-Risk Assessment of Medicines: Is This the Way Forward?

被引：27
|
作者：
Walker, Stuart [1 ,2 ]
McAuslane, Neil [1 ]
Liberti, Lawrence [1 ]
Leong, James [2 ,3 ]
Salek, Sam [2 ]
机构：
[1] Ctr Innovat Regulatory Sci, London EC1N 8JS, England
[2] Cardiff Univ, Sch Pharm & Pharmaceut Sci, Cardiff CF10 3AX, S Glam, Wales
[3] Hlth Sci Author, Singapore, Singapore
来源：
THERAPEUTIC INNOVATION & REGULATORY SCIENCE | 2015年 / 49卷 / 01期
关键词：
universal methodology for benefit-risk assessment; multicriteria decision making;
D O I：
10.1177/2168479014547421
中图分类号：
R-058 [];
学科分类号：
摘要：
A universal framework for the evaluation of the benefit-risk assessment of medicines during development by pharmaceutical companies and in the regulatory review by regulatory authorities is considered of value, as it would result in the systematic structured approach to support transparency in decision making. Several organizations have developed frameworks over the past few years, including those recommended by pharmaceutical companies such as the PhRMA BRAT (Pharmaceutical Research and Manufacturers of America Benefit-Risk Action Team) and the BRAIN (Benefit-Risk Assessment in New and Old Drugs) as well as frameworks advanced by regulatory agencies, including the FDA 5-step framework and the EMA PrOACT-URL. However, a review of the criteriaincluding logical soundness, comprehensiveness, acceptability of results, practicality, specificity and sensitivity, presentation (visualization), and scope proposed for the development of a universal frameworkdemonstrated that all these different frameworks described can be incorporated into UMBRA (Universal Methodology for Benefit-Risk Assessment).
引用
收藏
页码：17 / 25
页数：9
相关论文
共 50 条
  • [1] A Universal Framework for the Benefit-Risk Assessment of Medicines: Is This the Way Forward?
    Stuart Walker
    Neil McAuslane
    Lawrence Liberti
    James Leong
    Sam Salek
    Therapeutic Innovation & Regulatory Science, 2015, 49 : 17 - 25
  • [2] Is there a need for a universal benefit-risk assessment framework for medicines? Regulatory and industry perspectives
    Leong, James
    McAuslane, Neil
    Walker, Stuart
    Salek, Sam
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 (09) : 1004 - 1012
  • [3] Refining the Benefit-Risk Framework for the Assessment of Medicines: Valuing and Weighting Benefit and Risk Parameters
    Walker, S.
    Liberti, L.
    McAuslane, N.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (02) : 179 - 182
  • [4] Refining the Benefit-Risk Framework for the Assessment of Medicines: Valuing and Weighting Benefit and Risk Parameters (vol 89, pg 179, 2011)
    Walker, S.
    Liberti, L.
    McAuslane, N.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (06) : 928 - 928
  • [5] A Unified Framework for Classification of Methods for Benefit-Risk Assessment
    Najafzadeh, Mehdi
    Schneeweiss, Sebastian
    Choudhry, Niteesh
    Bykov, Katsiaryna
    Kohler, Kristijan H.
    Martin, Diane P.
    Gagne, Joshua J.
    VALUE IN HEALTH, 2015, 18 (02) : 250 - 259
  • [6] A UNIFIED FRAMEWORK FOR CLASSIFICATION OF METHODS FOR BENEFIT-RISK ASSESSMENT
    Najafzadeh, M.
    Schneeweiss, S.
    Choudhry, N. K.
    Bykov, K.
    Kahler, K.
    Martin, D.
    Arcona, S.
    Rogers, J. R.
    Gagne, J. J.
    VALUE IN HEALTH, 2014, 17 (03) : A3 - A3
  • [7] A Unified Framework for Classification of Methods for Benefit-Risk Assessment
    Najafzadeh, Mehdi
    Schneeweiss, Sebastian
    Choudhry, Niteesh K.
    Bykov, Kate
    Kahler, Kristijan
    Martin, Diane P.
    Arcona, Stephen
    Gagne, Joshua J.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 240 - 241
  • [8] Consideration of Benefit-Risk Assessment and Risk Management in Clinical Research of Traditional Medicines
    Zhang, L.
    Cong, J. L.
    Huang, J. K.
    Yang, X. H.
    DRUG SAFETY, 2018, 41 (11) : 1207 - 1207
  • [9] Development of a Framework for Enhancing the Transparency, Reproducibility and Communication of the Benefit-Risk Balance of Medicines
    Coplan, P. M.
    Noel, R. A.
    Levitan, B. S.
    Ferguson, J.
    Mussen, F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (02) : 312 - 315
  • [10] Measuring Benefit and Balancing Risk: Strategies for the Benefit-Risk Assessment of New Medicines in a Risk-Averse Environment
    Walker, S.
    McAuslane, N.
    Liberti, L.
    Salek, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (03) : 241 - 246
12345